Vertex reports 42.7% UACR reduction in Phase 2b AMKD trial
AI Summary- Vertex Pharmaceuticals reported Phase 2b inaxaplin data from two AMKD patient groups.
- 42.7% was the mean UACR reduction after 13 weeks in the modest-proteinuria cohort.
- Vertex completed enrollment in Phase 2/3 AMPLITUDE and expects interim results in early 2027.